(Shenzhen, May 20,2025) —— Today, Shenzhen-Hong Kong Cell Valley (Shenzhen) Medical Technology Co., Ltd. was officially opened in Qianhai Shenzhen-Hong Kong Youth Dream Workshop, marking the official launch of the project and heralding a new stage of in-depth cooperation between Shenzhen and Hong Kong in the field of cell therapy and biomedical industry. The grand opening ceremony attracted distinguished guests from political, academic, and industrial sectors. Attendees included Professor Jiang Yuyang, Vice Chairman of Shenzhen Municipal People's Congress Standing Committee and President of Shenzhen Association for Science and Technology; officials from Qianhai Administration Bureau; Dr. Zheng Jinzhong, Chairman of Hong Kong Cancer Foundation; Professor Yu Changhai, President of Hong Kong Biotechnology Association; along with experts, scholars, and corporate representatives from healthcare institutions and biopharmaceutical fields. In his opening address, Professor Shi Yuanyuan, founder of Shenzhen-Hong Kong Cell Valley, stated that the initiative will be based in Qianhai, Shenzhen, while maintaining close collaboration with Hong Kong. By fully integrating the strengths of both regions in scientific research, industrial development, and policy frameworks, the platform will establish a one-stop service system covering the entire cell and gene therapy value chain. This includes medical services, innovative drug R&D, manufacturing, healthcare, and anti-aging aesthetics. Supported by the Qianhai Free Trade Zone's policies, the project aims to accelerate the clinical translation and industrial application of cutting-edge technological achievements. In his speech, Professor Yu Changhai, Chairman of the Hong Kong Biotechnology Association, highlighted that the establishment of Shenzhen-Hong Kong Cell Valley exemplifies complementary strengths and collaborative innovation between the two regions. Hong Kong boasts significant advantages in biotech internationalization, scientific research accumulation, and talent reserves, while Shenzhen has been actively advancing technological innovation, industrial incubation, and policy support. The partnership between these two cities will inject fresh momentum into the biomedical industry within the Guangdong-Hong Kong-Macao Greater Bay Area. Under the witness of on-site guests, Shenzhen-Hong Kong Cell Valley held a grand opening ceremony, symbolizing the official launch of the project and embarking on a new journey for the industrial development of cell therapy. Additionally, three significant strategic cooperation agreements were signed at the event: 1. Collaborating with Academician Yan Xiyun's team from the Chinese Academy of Sciences to establish "Shenzhen Ecotype Cell Medicine Co., Ltd.", jointly developing the world's first CD146-CLL1 dual-target cell therapy drug 2. Strategic cooperation with The Hong Kong Greater China Cancer Foundation to become the foundation's partner in love, providing advanced cell therapy programs for patients in Hong Kong and the Greater Bay Area 3. Jointly build the "Cell Therapy Transformation Research Institute" with Shenzhen Hospital of Southern Medical University to create an innovation platform integrating research and development, transformation and clinical practice The launch of Shenzhen-Hong Kong Cell Valley marks not only a significant milestone in corporate development, but also a new starting point for deepening collaboration between the two cities in the biomedical industry. Moving forward, the valley will strengthen partnerships with global research institutions, universities, and industry partners to focus on breakthroughs in core technologies, accelerating the dual realization of clinical and commercial value in cell therapy applications.